EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries

Alex Durand Nka iD, Yagai Bouba iD, Wilfried Rooker Tsapi Lontsi, Davy-Hyacinte Gouissi Anguechia iD, Georges Teto, Aude Christelle Ka'e iD, Ezechiel Ngoufack Jagni Semengue iD, Collins Ambe Chenwi iD, Désiré Takou, Lum Forgwei, Tatiana Anim-Keng Tekoh, Aurelie Minelle Kengni Ngueko und 15 weitere

Viruses · 2025

DOI: 10.3390/v17010069 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Alex Durand Nka und 26 weiteren Autor:innen. Beteiligte Einrichtung: Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé P.O. Box 3077, Cameroon. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Reverse Transcriptase Inhibitors, Anti-HIV Agents. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Islatravir (ISL) is a novel antiretroviral that inhibits HIV-1 reverse transcriptase translocation. The M184V mutation, known to reduce ISL’s viral susceptibility in vitro, could arise from prolonged exposure to nucleoside reverse transcriptase inhibitors (NRTI) (3TC). This study evaluated the predictive efficacy of ISL and identified potentially active antiretrovirals in combination among treatment-experienced patients in Cameroon, where NRTIs (3TC) have been the backbone of ART for decades now. Although ISL is a long-acting antiretroviral, it will provide other therapeutic options in combination with other reverse transcriptase inhibitors that remain effective. We analyzed 1170 HIV-1 sequences from patients failing first-, second-, and third-line ART using the CIRCB Antiviral Resistance Evaluation (CIRCB-CARE) database. Drug resistance mutations (DRMs) were interpreted using Stanford HIVdb.v9, and covariation patterns between M184V and major NRTI/NNRTI DRMs were assessed. The study population, with a median age of 40 years, showed a high prevalence of resistance to NRTIs (77.4%) and NNRTIs (49.2%). The most frequent NRTI DRMs were M184V/I (83.3%), M41L (25.0%), and T215FY (36.8%), while common NNRTI DRMs included K103NS (53.3%), Y181CIV (27.7%), and G190ASE (22.2%). In first-line ART failure, M184V significantly covaried with K70R, L74I, and M41L for NRTIs and K103N and G190A for NNRTIs. In second-line failure, the covariation with M184V extended to T215Y, M41L, and D67N for NRTIs and G190A, K103N, and K103S for NNRTIs. No significant covariation with M184V was observed in third-line treatment failures. Based on these covariations and on the effect of these mutations on available anti-HIV drugs, TDF (partial efficacy) and Doravirine (fully active) were identified as potentially suitable candidates in combination with ISL among patients failing the first, second, and third lines, and could serve as a valuable therapeutic option in LMICs facing similar treatment challenges.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Reverse Transcriptase InhibitorsAnti-HIV AgentsTenofovirPyridonesHumansCameroonDrug Resistance, ViralAdultFemaleMaleHIV Reverse TranscriptaseMiddle AgedMutationDrug Therapy, CombinationYoung AdultDeoxyadenosinesTriazoles

Stichwörter der Autor:innen

CameroonHIVIslatravirtreatment-experienced patients

Substanzen

Reverse Transcriptase InhibitorsAnti-HIV AgentsdoravirineTenofovirPyridonesislatravirHIV Reverse TranscriptaseDeoxyadenosinesTriazoles

Autor:innen und Institutionen

  • Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management, Yaoundé P.O. Box 3077, Cameroon.
  • Faculty of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy.
  • Department of Microbiology, Faculty of Science, University of Yaoundé 1, Yaoundé P.O. Box 337, Cameroon.
  • Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
  • Department of Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, 00133 Rome, Italy.
  • Department of Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

ORCID-Profile: Alex Durand Nka, Yagai Bouba, Davy-Hyacinte Gouissi Anguechia, Aude Christelle Ka'e, Ezechiel Ngoufack Jagni Semengue, Collins Ambe Chenwi, Michel Carlos Tommo Tchouaket, Willy Leroi TognaPabo, Marcel Yotebieng, Maria-Mercedes Santoro, Joseph Fokam

Förderung

  • Chantal BIYA International Reference Centre for research on HIV/AIDS prevention and management (CIRCB)

Zitieren

APA

Nka, A. D., Bouba, Y., Tsapi Lontsi, W. R., Gouissi Anguechia, D. H., Teto, G., Ka'e, A. C., Semengue, E. N. J., Ambe Chenwi, C., Takou, D., Forgwei, L., Tekoh, T. A., Ngueko, A. M. K., Fokou, B. B., Efakika Gabisa, J., Tchouaket, M. C. T., TognaPabo, W. L., Ayuk Ngwese, D. T., Njiki Bikoi, J., Armenia, D., …, & Fokam, J. (2025). Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries. Viruses. https://doi.org/10.3390/v17010069

Vancouver

Nka AD, Bouba Y, Tsapi Lontsi WR, Gouissi Anguechia DH, Teto G, Ka'e AC, et al. Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries. Viruses. 2025. doi:10.3390/v17010069

BibTeX
@article{Nka2025,
  author = {Nka, Alex Durand and Bouba, Yagai and Tsapi Lontsi, Wilfried Rooker and Gouissi Anguechia, Davy-Hyacinte and Teto, Georges and Ka'e, Aude Christelle and Semengue, Ezechiel Ngoufack Jagni and Ambe Chenwi, Collins and Takou, Désiré and Forgwei, Lum and Tekoh, Tatiana Anim-Keng and Ngueko, Aurelie Minelle Kengni and Fokou, Bernadette Bomgning and Efakika Gabisa, Jeremiah and Tchouaket, Michel Carlos Tommo and TognaPabo, Willy Leroi and Ayuk Ngwese, Derrick Tambe and Njiki Bikoi, Jacky and Armenia, Daniele and Colizzi, Vittorio and Yotebieng, Marcel and Ndembi, Nicaise and Santoro, Maria-Mercedes and Ceccherini-Silberstein, Francesca and Perno, Carlo-Federico and Ndjolo, Alexis and Fokam, Joseph},
  title = {Tenofovir and Doravirine Are Potential Reverse-Transcriptase Analogs in Combination with the New Reverse-Transcriptase Translocation Inhibitor (Islatravir) Among Treatment-Experienced Patients in Cameroon: Designing Future Treatment Strategies for Low- and Middle-Income Countries},
  journal = {Viruses},
  year = {2025},
  doi = {10.3390/v17010069}
}
Kostenlos starten →